XML 61 R39.htm IDEA: XBRL DOCUMENT

Collaborative and Other Relationships (Tables)

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Activity Related to BAN2401 and Elenbecestat Collaboration



(In millions)		For the Three Months Ended March 31, 2020
Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat		$	43.5
Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income		$	21.8
Total sales and marketing expense incurred by the collaboration		$	4.9
Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income		$	2.4

Summary of Activity Related to Aducanumab Collaboration

A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:



		For the Three Months Ended March 31,
(In millions)		2020				2019
Total aducanumab development expense		$	19.1			$	162.5
Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income		$	10.5			$	89.4
Total aducanumab sales and marketing expense		$	22.7			$	20.9
Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income		$	12.3			$	11.6